Abstract: Aim: To evaluate the effect of Mifepristone for the treatment of leiomyomata uteri.
Materials and Methods: A total of 50 women who attended gynaecological outpatient department with various symptoms associated with leiomyoma uteri were taken up for the study. Routine blood investigations including complete blood count, renal function tests, liver function tests were done. Pelvic ultra sound and Endometrial sampling were performed. The women were administered 25 mg of Mifepristone daily starting from D1-D3 of menstrual cycle for a period of 3 months. The women were followed up at the end of 3 months and after 6 months for betterment of their symptoms, improvement in their haemoglobin status, alteration in their biochemical tests like LFT, RFT. Endometrial sampling was performed at the end of 3 months of treatment. Efficacy was estimated by the reduction in the volume of fibroids, size of uterus on follow up ultra sound scans at 3 and 6 months, and improvement in quality of life.
Results: There was a significant decrease in size of uterus in 68% of women and the volume of fibroids decreased on an average to 54.8% following treatment. There was a reduction in the amount of menstrual flow in 84% of women. 22% of women reported hypomenorrhoea, 26% of women reported oligomenorrhoea, 8% reported amenorrhoea during the course of the treatment which was reversible after the completion of treatment. Almost all of them resumed regular menstruation by 6 months. Women also had significant improvement in quality of life as there was symptomatic relief and improvement of their haemoglobin levels.
Conclusion: Mifepristone in the dosage of 25mg on a short course produced significant reduction in leiomyoma volume, uterine size and produced symptomatic improvement in women with fibroids.